Purpose: This study evaluated the efficacy of TiaoPi AnChang Decoction (TPACD) against CAPOX-induced adverse reactions (CIARs) and improving survival outcomes in colorectal cancer (CRC) patients receiving CAPOX as adjuvant chemotherapy. This paper presents an interim analysis of the clinical trial, with a primary focus on CIARs. Patients and methods: This was a randomized, double-blind, placebo-controlled trial enrolling high-risk stage II or III CRC patients undergoing CAPOX who were diagnosed with spleen-kidney deficiency syndrome. The study planned to randomly assign 98 patients in a 1:1 ratio to either the TPACD group (30 mL orally, twice daily) or the placebo group (matched placebo). The trial duration spanned 4 chemotherapy cycles (approximately 84 days), during which we assessed the incidence of CIARs (graded via CTCAE), Traditional Chinese Medicine (TCM) syndrome scores, quality of life (QoL, evaluated via EORTC QLQ-C30), peripheral blood immune cell subsets, tumor markers, safety, and survival outcomes. A linear mixed-effects model was applied to adjust for baseline differences. Results: Among 496 screened CRC patients, 108 were randomized into the TPACD group (n = 54) or the placebo group (n = 54). The incidence of overall CIARs was significantly lower in the TPACD group ( P = 0.009), particularly for grade ≥2 CIARs (37.77% vs. 67.70%, P = 0.008). Subgroup analyses revealed that the treatment effect was homogeneous, with no significant interaction observed between the treatment and the variables of age, sex, BMI, tumor size, or TNM stage (all P for interaction >0.05). TPACD administration resulted in improvements in symptoms including fatigue, nausea, vomiting, loss of appetite, and oxaliplatin-induced peripheral neuropathy. However, its efficacy in alleviating myelosuppression, hand-foot syndrome, and pain was limited. Additionally, TPACD improved overall QoL (least squares mean difference (LSMD) −11.71, P < 0.001), attenuated the progression of spleen-kidney deficiency syndrome (LSMD 3.09, P < 0.001), and positively influenced the CD4+/CD8+ ratio (1.91 ± 0.94 vs. 2.64 ± 1.04, P = 0.002). No additional hepatic or renal injury was observed. The predefined endpoints for survival outcomes had not been reached at the time of this analysis. Conclusion: TPACD serves as an effective, safe, well-tolerated, and readily acceptable complementary therapy for CRC patients undergoing CAPOX. Clinical Trial Registration: https://www.chictr.org.cn/index.html , identifier ChiCTR2200065759.